Condition: Portal Hypertension Related to Cirrhosis · Sponsor: Universitaire Ziekenhuizen KU Leuven
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.
This description comes directly from the study's public registry record.
Emma Vanderschueren, MD · 0032 16 345918 · emma.vanderschueren@uzleuven.be
Petra Windmolders · 003216 347581 · petra.windmolders@uzleuven.be
Always discuss trial participation with your own doctor first.
| University Hospital Leuven | Leuven, Vlaams-Brabant, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06513195